Tarpeyo (budesonide) — Point32Health
Primary immunoglobulin A nephropathy (IgAN) in adults who are at risk of rapid disease progression
Initial criteria
- Documented diagnosis of immunoglobulin A nephropathy confirmed by kidney biopsy
- Documented urine protein-to-creatinine ratio (UPCR) of at least 1.5 g/g OR proteinuria ≥ 1 g/day
- Documented estimated glomerular filtration rate of at least 35 mL/min/1.73 m2
- Prescribed by or in consultation with a nephrologist
- Documentation that the patient has not developed end stage renal disease by requiring either dialysis or a kidney transplant
- Documentation that the member has received or is currently receiving at least 3 months of therapy with an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) at up to maximally indicated doses, unless contraindicated or not tolerated
- Documentation that the member has received or is currently receiving at least 3 months of therapy with a sodium-glucose cotransporter-2 inhibitor (SGLT2i), unless contraindicated or not tolerated
- Documentation that the member has received optimized supportive care for at least 3 months, including blood pressure management, lifestyle modification, and cardiovascular risk modification
Approval duration
9 months